01—Abstract
Summary
Summary of the 10-K filed March 28, 1997. Cited figures are marked; the original filing is the authoritative source.
Pfizer's 1996 Form 10-K shows a strong year driven by volume growth in its core pharmaceutical franchise.
Net sales rose 13% to $11.3 billiona, net income increased 23% to $1.93 billion, and EPS grew 20% to $2.99. The Health Care segment generated 85% of revenue ($9.6 billion, up 15%), with pharmaceuticals at $8.2 billion (up 16%). Three products (Norvasc, Zoloft and Procardia XL) each exceeded $1 billion in sales, and the company describes a pipeline of 13 new chemical entities in late-stage development or regulatory review.
Gross margin improved as cost of sales fell to 19.3%b of sales from 21.6%, and the effective tax rate dropped to 31.0% from 32.1%. The filing also highlights meaningful risks. Pfizer relies heavily on a small number of products, and Procardia XL faces future competition from other sustained-release nifedipine products, with its patent protected until 2003.
Feldene and Glucotrol have already lost U.S. exclusivity to generics. Managed care pressure, Medicaid rebate obligations and possible U.S. health care reform are flagged as pricing headwinds for 1997. The company also discloses extensive litigation, including Shiley heart valve claims, pharmacy antitrust suits, asbestos claims, and a Brazilian civil action with a potential payment of about $88 millionc, though management consistently states these should not have a material adverse effect.
Financial strength remained solid. Operating cash flow reached $2.07 billiond, and debt to total capitalization fell to 30% from 34%.
Senior debt carried Aaa/AAA ratings for the 11th consecutive year. Management plans to raise 1997 R&D spending to about $2.0 billion, and the board has proposed a two-for-one stock split, subject to shareholder approval of more authorized shares at the April 1997 annual meeting.
02—Key points
Key Highlights
- Net sales grew 13% to $11,306 million in 1996, driven primarily by volume gains across the portfolio.
- Net income rose 23% to $1,929 million ($2.99 per share, up 20%), supported by operating leverage and a lower effective tax rate of 31.0%.
- Three products exceeded $1 billion in 1996 sales: Norvasc ($1.8 billion, up 42%), Zoloft ($1.3 billion, up 29%) and Procardia XL ($1.0 billion, down 11%).
- R&D spending rose 17% to $1.7 billion in 1996, with 2026 plans targeting about $2.0 billion in 1997 and 13 new chemical entities in late-stage development or regulatory review.
- Operating cash flow was $2.07 billion, and debt to total capitalization improved to 30% from 34%, with Aaa/AAA senior debt ratings maintained.
- Key risks include generic erosion (Feldene, Glucotrol), Procardia XL competition ahead of its 2003 patent expiry, U.S. managed care and Medicaid pricing pressure, and significant product liability and antitrust litigation.
- The board proposed a two-for-one stock split to be voted on April 24, 1997, subject to shareholder approval of additional authorized shares.
03—Questions
Frequently Asked Questions
What drove Pfizer's revenue growth in 1996?
Revenue growth was driven mainly by volume, which contributed 15 percentage points of the 13% increase. Pharmaceuticals grew 16% to $8.2 billion, led by Norvasc, Zoloft and Zithromax. Animal Health was flat at $1.2 billion, while Consumer Health Care grew 15% to $454 million, helped by recently acquired brands.
How exposed is Pfizer to patent expirations and generic competition?
Exposure is significant. Feldene and Glucotrol have faced generic competition since 1992 and 1994, with combined U.S. sales falling to $59 million in 1996 from $203 million in 1994. Procardia XL, which had $1.0 billion in sales, faces potential competition from other sustained-release nifedipine products, though its delivery-system patent runs until 2003. Basic patents on Norvasc, Zoloft and Diflucan run into the 2004 to 2007 period. Management notes that a product's sales can drop sharply within a year of losing exclusivity.
Are there material legal or regulatory risks disclosed?
Yes. The filing lists numerous matters, including Shiley heart valve claims, pharmacy antitrust class actions, asbestos personal injury suits, the Plax FDA proceedings, a Zoloft promotional-materials Warning Letter, and a Brazilian civil action that could require a payment of about $88 million. Pfizer also faces Belgian and U.S. tax assessments, with the Belgian assessment described as approximately $432 million in taxes plus interest. Management consistently states that these matters should not have a material adverse effect on the financial position or results of operations.
How strong is Pfizer's balance sheet and shareholder return policy?
The balance sheet strengthened. Shareholders' equity rose to $6.95 billion from $5.51 billion, and debt to total capitalization fell to 30%. Cash dividends increased 15% to $1.20 per share, marking the 29th consecutive year of dividend increases. The company also authorized a $2 billion share repurchase program over 18 to 24 months, though only about 300,000 shares were bought back in 1996.
04—Continue